Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 9.0× sales vs its 15.5× historical median P/S.
Fair value ≈ $0.02 · price $0.01 today
Undervalued · 42% below
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$BBRRF Q1 2026 financial results ending 3/31/26 were just released after the closed today 5/28/26.
Revenues still lower compared to same time period last year.
Not good. Once again very disappointing. 🤷♂️
$BBRRF Is traceability the most important ingredient in your pharmaceutical formulation? 🔍
In the healthcare industry, the quality of an ingredient is not defined solely by its purity, but by the strength of the documentation that supports it.
When evaluating a pharmaceutical CBD supplier, the real question is:
Is your ingredient ready to pass audits, regulatory processes and international standards? 📋
At BLUEBERRIES, we understand that regulatory compliance is not a differential: it is the foundation of patient safety and commercial success.
That is why we work on three key pillars:
🧪 Pharmaceutical Grade Documentation
Complete Certificates of Analysis (CoA), technical specifications and full lot-to-lot traceability.
🌿 Transparency throughout the chain
From the botanical origin to the extraction and purification process, each stage is documented under strict quality and compliance standards.
🛠️ Specialized technical and regulatory support
$BBRRF Brazil is consolidating itself as the epicenter of innovation in Cannabis and Blueberries is present.
This week, the eyes of the industry in Latin America are on São Paulo with the celebration of the Cannabis Fair, a key space where medicine, technology, cultivation and business converge in a rapidly expanding market that already exceeds 800,000 patients registered in the country.
At Blueberries, we understand that the future of medicinal cannabis applications depends not only on the genetics of the plant, but on the purity and precision of the final ingredient.
For this reason, our approach is aligned with the demands of a market as demanding as Brazil's:
🔬 High-Precision Medicinal Applications: We support the development of advanced treatments for human and veterinary health, where cannabinoid consistency is critical to clinical efficacy.
⚡ Supercritical CO₂ Extraction Technology: How do we achieve it? Through state-of-the-art process engineering.
$BBRRF
Found Nutripharma on Amazon:
I've shared a Brand Store on Amazon with you. https://www.amazon.com/stores/NUTRIPHARMAQuickSlim/page/C10F85A5-32BA-4B9C-B0AF-52CBEAB86CC5?lp_asin=B09PZBB5Y6&ref_=cm_sw_r_apann_ast_store_RTDJ23THN98DW9ZB8MVB&store_ref=bl_ast_dp_brandlogo_sto
$BBRRF audited financial results came out tonight and they don’t look good.
The last three months of 2025 vs 2024 revenue was down almost 90%
Comparing annual revenue for 2024 versus 2025 roughly 30% less
Enough said. Huge disappointment…
$BBRRF
Potential For Mass Success
Efficiency and Consistency: In traditional agriculture, active ingredient levels fluctuate due to weather. This biotech model ensures every batch is identical, which is critical for pharmaceutical and high-end cosmetic standards.
Financial Growth: Terraflos has projected roughly $20 million in earnings for 2026, with a stated growth rate of 100% annually.
Market Tailwinds: The global biotechnology market is projected to reach $4.41 trillion by 2031. As consumers shift toward "clean" and "science-backed" ingredients, Terraflos is positioned to supply the molecules driving this demand.
$BBRRF last week and this week as of this moment, I’ve picked up additional 300,000 shares of BBRRF at $0.0100 (3 pieces at 100,000 at 0.01 All or none). Full year 2025 audited financials should be released by April 30th per past history. Last year (early March 2025) they issued more shares because they needed more money to run the company aka dilution. They did not do that this year and the director is keeping his word and buying shares at one cent randomly when the stock drops below one cent. My thinking is that the revenue will finally pick up because if it doesn’t, then why would the director continue to buy shares at one cent knowing they’re gonna tank (share price) once earnings are released. Let’s hope our patience will finally be rewarded 🤞
